AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24389933 — intervention group
Group type: EXPERIMENTAL
Intervention: Denervation of the patella
Number of subjects: 71
Study 24389933 — intervention group
Group type: COMPARATOR
Intervention: No denervation of the patella
Number of subjects: 71
Study 22467107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration (16 IU)
Number of subjects: 57
Study 22467107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 19440519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 4763
Study 19440519 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4763
Study 19440519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 4763
Study 19440519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both genders
Number of subjects: 4763
Study 17314587 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (paroxetine or citalopram)
Number of subjects: 101
Study 17314587 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 101
Study 17179461 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD programming techniques
Number of subjects: 0
Study 17179461 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medications
Number of subjects: 0
Study 17179461 — intervention group
Group type: COMPARATOR
Intervention: ICD shocks (both appropriate and inappropriate)
Number of subjects: 0
Study 14710804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise therapy
Number of subjects: 24
Study 10390212 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (600 mg) intravenously twice daily for 5 days
Number of subjects: 0
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cold blood cardioplegia
Number of subjects: 62
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cold blood cardioplegia
Number of subjects: 62
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus occlusion during antegrade supply
Number of subjects: 62
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major vessel disease and reduced left ventricular function
Number of subjects: 62
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with aortic cross-clamp times of more than 1 h
Number of subjects: 62
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial temperature of 22 +/- 3 degrees C before terminal cardioplegia
Number of subjects: 62
Study 8664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated myoglobin peaks within 1 h after aortic declamping
Number of subjects: 62
Study 1799889 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg
Number of subjects: 15
Study 1799889 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg
Number of subjects: 15
Study 1799889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6365208 — intervention group
Group type: EXPERIMENTAL
Intervention: PF therapy (1-phenylalanine mustard and 5-fluorouracil)
Number of subjects: 0
Study 28114735 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (25 mg oral single dose) with glibenclamide (5 mg) and metformin (500 mg)
Number of subjects: 26
Study 28114735 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg oral single dose) in type 2 diabetes mellitus patients
Number of subjects: 26
Study 26114297 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal vaccination with one dose of 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 7810
Study 26114297 — intervention group
Group type: COMPARATOR
Intervention: Current practice (vaccination of institutionalized elderly and elderly with underlying diseases)
Number of subjects: 7810
Study 23052228 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate 5 mg
Number of subjects: 22
Study 23052228 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 20497640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) + inhaled corticosteroids (ICS)
Number of subjects: 32
Study 20497640 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) alone
Number of subjects: 32
Study 18924528 — intervention group
Group type: EXPERIMENTAL
Intervention: Faustlos violence prevention program
Number of subjects: 13
Study 16422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Contact Tonometer (NCT)
Number of subjects: 352
Study 16422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal Dynamic Contour Tonometer (DCT)
Number of subjects: 352
Study 16422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Corneal Thickness (CCT)
Number of subjects: 352
Study 12591753 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT1 during exercise stress test
Number of subjects: 82
Study 12591753 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT2 during exercise stress test
Number of subjects: 82
Study 12591753 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 82
Study 10363395 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional stabilization (elastic adhesive bandaging for 7 days without support)
Number of subjects: 80
Study 10363395 — intervention group
Group type: COMPARATOR
Intervention: Orthopedic stabilization (subsequent ferule for 21 days)
Number of subjects: 80
Study 8905424 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 72 mg/kg i.v. as a bolus, later 72 mg/kg over 12 h
Number of subjects: 18
Study 8905424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no premedication)
Number of subjects: 18
Study 1867454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50, 200, or 800 micrograms twice daily for 4 weeks
Number of subjects: 97
Study 1867454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 6347382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (1%) vaginal cream for seven days
Number of subjects: 93
Study 6347382 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole (2%) vaginal cream for seven days
Number of subjects: 93
Study 6347382 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (1%) vaginal cream
Number of subjects: 93
Study 6347382 — intervention group
Group type: COMPARATOR
Intervention: Miconazole (2%) vaginal cream
Number of subjects: 93
Study 6347382 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive use
Number of subjects: 93
Study 31466807 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving self‐management support program (six bi‐weekly social support group sessions)
Number of subjects: 41
Study 31466807 — intervention group
Group type: COMPARATOR
Intervention: Telephone instructions (three monthly instructions)
Number of subjects: 41
Study 31576437 — intervention group
Group type: EXPERIMENTAL
Intervention: Na154 (154 mmol/L sodium)
Number of subjects: 70
Study 31576437 — intervention group
Group type: COMPARATOR
Intervention: Na54 (54 mmol/L sodium)
Number of subjects: 70
Study 28372526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive metformin (n=253)
Number of subjects: 509
Study 28372526 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=256)
Number of subjects: 509
Study 25525759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanorap (topical application of 2 g)
Number of subjects: 0
Study 24295006 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional steel bur
Number of subjects: 30
Study 24295006 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 30
Study 24295006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical method
Number of subjects: 30
Study 21224335 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin Physique Salient (TPS) video
Number of subjects: 99
Study 21224335 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin Physique Non-Salient (TPNS) video
Number of subjects: 99
Study 19763753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lens with an 8.8-mm base curve
Number of subjects: 27
Study 19763753 — intervention group
Group type: COMPARATOR
Intervention: Bandage contact lens with an 8.4-mm base curve
Number of subjects: 27
Study 17826453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory retraining of the more affected lower limb
Number of subjects: 21
Study 17826453 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (sham intervention)
Number of subjects: 21
Study 15497366 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(‐1) body mass, initial dose)
Number of subjects: 12
Study 15497366 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg x kg(‐1) body mass, re-dose)
Number of subjects: 12
Study 15497366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10678627 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training (12 week hospital outpatient programme)
Number of subjects: 43
Study 10678627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight training)
Number of subjects: 43
Study 9083710 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (20-mg wafer)
Number of subjects: 829
Study 9083710 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150-mg tablet)
Number of subjects: 829
Study 1443471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - statements about common facts of some years ago
Number of subjects: 43
Study 1443471 — intervention group
Group type: COMPARATOR
Intervention: Group B - new verbal associations, i.e. names of fictitious, nonfamous people
Number of subjects: 43
Study 3574641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily for 6 days
Number of subjects: 88
Study 3574641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg for 2 weeks followed by 40 mg for 3 weeks
Number of subjects: 88
Study 3574641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 31116186 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm short implants
Number of subjects: 30
Study 31116186 — intervention group
Group type: COMPARATOR
Intervention: 10-mm long implants
Number of subjects: 30
Study 28616919 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral immune nutrition for 7 days
Number of subjects: 60
Study 28616919 — intervention group
Group type: COMPARATOR
Intervention: Normal nutrition
Number of subjects: 60
Study 26438161 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human interleukin‐1 receptor antagonist)
Number of subjects: 50
Study 26438161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg alone
Number of subjects: 40
Study 22946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg with verapamil 120 mg immediate release given 1 hour before DE
Number of subjects: 40
Study 22946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg with verapamil 240 mg extended release
Number of subjects: 40
Study 22946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg after multiple verapamil dosing
Number of subjects: 40
Study 22946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg given 2 hours before verapamil
Number of subjects: 40
Study 22946890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) with verapamil
Number of subjects: 40
Study 21455785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Laser Therapy (LILT) using combined He-Ne and infrared lasers
Number of subjects: 30
Study 21455785 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study 21455785 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 19555315 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg capsules, three times daily for 14 days)
Number of subjects: 18
Study 19555315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17725186 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program 'I keep cool'
Number of subjects: 143
Study 17725186 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 15167085 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.60 mg/kg b.i.d.
Number of subjects: 24
Study 15167085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11475920 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50-75 mgs/day)
Number of subjects: 40
Study 11475920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mgs/day)
Number of subjects: 40
Study 10450271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 154
Study 10450271 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 154
Study 10450271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 7653432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0
Study 7653432 — intervention group
Group type: COMPARATOR
Intervention: Bethanechol and Metoclopramide
Number of subjects: 0
Study 7653432 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0
Study 2167452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (500 mg/kg weekly to day 90, then monthly to day 360 after transplantation)
Number of subjects: 382
Study 2167452 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given immunoglobulin)
Number of subjects: 382
Study 2167452 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study 2167452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 382
Study 376572 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 22
Study 376572 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 22
Study 376572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 22
Study 30149825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy - Long (CBT-L)
Number of subjects: 100
Study 30149825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy - Brief (CBT-B)
Number of subjects: 100
Study 30149825 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 100
Study 28593413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (100,000 units/10 kg)
Number of subjects: 70
Study 28593413 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 70
Study 26222044 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion (NB32)
Number of subjects: 3362
Study 26222044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3362
Study 24261187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib 0.3 mg
Number of subjects: 28
Study 24261187 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab 1.25 mg
Number of subjects: 28
Study 21210134 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hCG (100 IU/day) with reduced r‐FSH (75 IU) after lead follicle reached 14 mm
Number of subjects: 90
Study 21210134 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hCG (200 IU/day) with discontinued r‐FSH after lead follicle reached 14 mm
Number of subjects: 90
Study 21210134 — intervention group
Group type: COMPARATOR
Intervention: r‐FSH only (control group) until oocyte retrieval
Number of subjects: 90
Study 19788471 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan (twice daily)
Number of subjects: 416
Study 19788471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 16499880 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-089 2 mg b.i.d.
Number of subjects: 11
Study 16499880 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-089 4 mg b.i.d.
Number of subjects: 11
Study 16499880 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-089 20 mg b.i.d.
Number of subjects: 11
Study 16499880 — intervention group
Group type: COMPARATOR
Intervention: ABT-089
Number of subjects: 11
Study 14555796 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients
Number of subjects: 109
Study 14555796 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon and rectum polyps patients
Number of subjects: 109
Study 14555796 — intervention group
Group type: COMPARATOR
Intervention: Colorectal cancer patients, polyps patients, and control group
Number of subjects: 109
Study 14555796 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer tissue
Number of subjects: 109
Study 10772694 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 36
Study 9025426 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous double electric breast pumping system
Number of subjects: 9
Study 9025426 — intervention group
Group type: COMPARATOR
Intervention: Sequential single electric breast pumping system
Number of subjects: 9
Study 10171162 — intervention group
Group type: COMPARATOR
Intervention: Centrifugal pump (C group)
Number of subjects: 50
Study 10171162 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pump (R group)
Number of subjects: 50
Study 10171162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 6835893 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg meptazinol
Number of subjects: 9
Study 6835893 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg meptazinol
Number of subjects: 9
Study 6835893 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg meptazinol
Number of subjects: 9
Study 6835893 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of meptazinol
Number of subjects: 9
Study 3514702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole 1% cream for 1 week
Number of subjects: 60
Study 3514702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole 1% cream for 2 weeks
Number of subjects: 60
Study 28681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel three-month smoking cessation intervention
Number of subjects: 38
Study 28681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 38
Study 28681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to quit smoking
Number of subjects: 38
Study 28681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from educators
Number of subjects: 38
Study 28681572 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic smoking cessation components and education about smoking and RA
Number of subjects: 38
Study 26674982 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 240
Study 26674982 — intervention group
Group type: COMPARATOR
Intervention: Non-Eicosapentaenoic acid (non-EPA)
Number of subjects: 240
Study 25541827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sausalin at a dose of 720 mg/day
Number of subjects: 250
Study 25541827 — intervention group
Group type: COMPARATOR
Intervention: Ornidazole at a dose of 1500 mg/day
Number of subjects: 250
Study 25541827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sausalin
Number of subjects: 250
Study 25541827 — intervention group
Group type: COMPARATOR
Intervention: Ornidazole
Number of subjects: 250
Study 22973092 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 50 μg once daily
Number of subjects: 108
Study 22973092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 20597951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide gel 4%
Number of subjects: 8
Study 20597951 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 8
Study 18777603 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (standard open discectomy)
Number of subjects: 1191
Study 18777603 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care (usual nonoperative care)
Number of subjects: 1191
Study 15930418 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 38546
Study 15930418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38546
Study 12942871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soy milk (200 ml daily)
Number of subjects: 44
Study 12942871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 ml chemically fermented)
Number of subjects: 44
Study 10803764 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoietin alfa (Group A)
Number of subjects: 31
Study 10803764 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 31
Study 8636593 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine electrocardiogram (EKG) during follow-up visits
Number of subjects: 71
Study 1354086 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol, 200 mg o.d.
Number of subjects: 173
Study 1354086 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 100 mg o.d.
Number of subjects: 173
Study 6230888 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 6230888 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 0
Study 6230888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30616140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-charge electrotherapy (LCE), administered three times a week, approximately 2.8 Joules
Number of subjects: 12
Study 30616140 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 12
Study 29416219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level pressure support (PSV) up to 7 cmH2O
Number of subjects: 520
Study 29416219 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 520
Study 27412415 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination after isoniazid preventive therapy (IPT)
Number of subjects: 72
Study 27412415 — intervention group
Group type: COMPARATOR
Intervention: BCG revaccination without prior IPT
Number of subjects: 72